ArticleJournal of neurology2017
Severe refractory CIDP: a case series of 10 patients treated with bortezomib.
Article in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Clinical course and prognosis of chronic autoimmune neuropathies requiring intensive care: a retrospective cohort study.Journal of neurology · 2026Article
- Advances in the treatment of autoimmune nodopathy: based on treatment strategies of CIDP.Frontiers in immunology · 2026Review
- Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy.BMJ neurology open · 2025Review
- Insights into refractory chronic inflammatory demyelinating polyneuropathy: a comprehensive real-world study.Frontiers in neurology · 2024Article
- Chronic Inflammatory Demyelinating Polyneuropathy and Evaluation of the Visual Evoked Potentials: A Review of the Literature.Medicina (Kaunas, Lithuania) · 2023Review
- IgG4 Autoantibodies in Organ-Specific Autoimmunopathies: Reviewing Class Switching, Antibody-Producing Cells, and Specific Immunotherapies.Frontiers in immunology · 2022Review
- Mechanisms of Chemotherapy-Induced Neurotoxicity.Frontiers in pharmacology · 2022Review
- Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.Inflammopharmacology · 2021Review
- Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back.Experimental neurology · 2021Review
- Bortezomib in autoimmune hemolytic anemia and beyond.Therapeutic advances in hematology · 2021Review
- Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study.Therapeutic advances in neurological disorders · 2021Article
- Maintenance therapy with subcutaneous immunoglobulin in a patient with immune-mediated neuropathic postural tachycardia syndrome.Journal of translational autoimmunity · 2021Article
- Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis.Brain communications · 2021Article
- Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy.Neurological research and practice · 2020Review
- Progress in Hematopoietic Stem Cell Transplantation for CIDP.International journal of medical sciences · 2020Review
- General principles and escalation options of immunotherapy in autoantibody-associated disorders of the CNS.Neurological research and practice · 2019Review
- Capsaicin-enriched diet ameliorates autoimmune neuritis in rats.Journal of neuroinflammation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment options for patients with aggressive chronic inflammatory demyelinating neuropathy are limited and include the anti-CD20 antibody rituximab and the immunosuppressive regime cyclophosphamide. We aimed to investigate retrospectively the efficacy of bortezomib, a proteasome inhibitor tackling highly metabolically active cell types such as plasma cells, in a case series of 10 treatment refractory CIDP patients. All patients reported showed a deterioration of the clinical CIDP scores under first-line treatment or escalating treatment with cyclophosphamide or rituximab. One or two cycles of bortezomib treatment (each cycle with 1.3 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.